Tenapanor for Chronic Constipation

This trial aims to test the safety and effectiveness of a drug called tenapanor for people with chronic constipation of unknown cause. Participants will receive one of three different doses of tenapanor or a placebo (a pill with no active drug) to evaluate the drug's effectiveness over 26 weeks. Those experiencing persistent constipation without a known medical cause might find this trial suitable. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.

The trial protocol mentions that certain medications are prohibited, but it does not specify which ones. It's best to discuss your current medications with the trial team to see if they are allowed.

Research has shown that tenapanor is generally well-tolerated by patients. In one study on a similar condition, more participants taking tenapanor experienced side effects compared to those on a placebo (a pill with no active medicine). Diarrhea was the most common side effect, occurring in 16% of patients on tenapanor, compared to 4% on the placebo.

Other studies indicate that tenapanor remains tolerable even with long-term use, such as over 52 weeks, with safety results similar to those in shorter studies. While some individuals experience side effects, many find the treatment manageable over time.

Researchers are excited about Tenapanor for chronic constipation because it offers a novel approach compared to existing treatments like fiber supplements, osmotic laxatives, and stimulant laxatives. Tenapanor works by inhibiting the NHE3 transporter in the gut, which reduces sodium absorption and increases water in the intestines, easing bowel movements. This unique mechanism not only makes Tenapanor stand out from the standard treatments but also has the potential to offer relief with fewer side effects and improved comfort for patients.

Research shows that tenapanor may help treat constipation, particularly in individuals with irritable bowel syndrome with constipation (IBS-C). Earlier studies found that tenapanor significantly increased bowel movement frequency, with patients experiencing an increase from about 0.1 to more than 3 complete bowel movements per week over 26 weeks. Over 70% of patients reported improved ability to participate in daily activities. These findings suggest tenapanor could be an effective long-term treatment for managing chronic constipation symptoms. Participants in this trial will receive different dosages of tenapanor or a placebo to further evaluate its effectiveness.²⁶⁷⁸⁹